-

ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)

VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021.

Jennifer Bath, CEO of ImmunoPrecise, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: H.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)

Date: September 13-15, 2021

Presentation Day & Time: September 10, 6:00 PM (EDT)

Location: https://journey.ct.events/view/8a904567-5abc-4305-b0af-d61d08691320

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

Contacts

Investors:
LifeSci Advisors
John Mullaly
Email: jmullaly@lifesciadvisors.com

Industry:

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$XBI
Hashtags
#Deltavariant
#POLYTOPE
#antibodies
#cancer
#covid19
#inflammation
#leadership
#mutations
#nanomedicine
#oncology
#vaccines

Contacts

Investors:
LifeSci Advisors
John Mullaly
Email: jmullaly@lifesciadvisors.com

Social Media Profiles
ImmunoPrecise Antibodies
ImmunoPrecise Antibodies
ImmunoPrecise’s Substack Newsletter
ImmunoPrecise Antibodies
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

VICTORIA, British Columbia--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today launched ReefIQ™, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, li...

MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (Nasdaq: HYFT) today reported preclinical dengue data that support a computational prediction its HYFT® platform generated before any animal was immunized. HYFT® computationally identified a candidate pan-serotype structural target on the dengue virus. The subsequent immunization data support that prediction at the antibody-binding level: animals immunized with immunogens designed on the predicted target generated antibodies that cross-rea...

MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT® biological pattern system and LensAI™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. The Platform draws on the same biological intelligence in...
Back to Newsroom